Compare CARE & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CARE | FULC |
|---|---|---|
| Founded | 1974 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.1M | 467.8M |
| IPO Year | 2020 | 2019 |
| Metric | CARE | FULC |
|---|---|---|
| Price | $26.41 | $6.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $25.00 | $16.38 |
| AVG Volume (30 Days) | 311.5K | ★ 677.6K |
| Earning Date | 04-23-2026 | 04-27-2026 |
| Dividend Yield | ★ 0.40% | N/A |
| EPS Growth | ★ 30.19 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $20,315,000.00 | N/A |
| Revenue This Year | $12.50 | N/A |
| Revenue Next Year | $11.82 | N/A |
| P/E Ratio | $19.00 | ★ N/A |
| Revenue Growth | ★ 4.65 | N/A |
| 52 Week Low | $15.48 | $5.47 |
| 52 Week High | $26.58 | $15.74 |
| Indicator | CARE | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 76.40 | 40.99 |
| Support Level | $19.34 | $6.39 |
| Resistance Level | N/A | $7.09 |
| Average True Range (ATR) | 0.68 | 0.47 |
| MACD | 0.06 | -0.06 |
| Stochastic Oscillator | 92.51 | 10.81 |
Carter Bankshares Inc is a bank holding company that conducts its business solely through the bank. The Bank earns revenue from interest on loans and securities and fees charged for financial services provided to customers. It offers a full range of deposit services including Lifetime Free Checking, interest checking accounts, savings accounts, retirement accounts and other deposit accounts of various types, ranging from money market accounts to longer-term CDs. The Bank offers a full range of commercial and consumer loans. The Bank also originates and holds fixed and variable-rate mortgage loans and offers home equity lines of credit to its customers.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.